Screener
BridgeBio Pharma BBIO Gain (loss) on extinguishment of debt
Gain (loss) on extinguishment of debt at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's gain (loss) on extinguishment of debt?
- BridgeBio Pharma (BBIO) reported gain (loss) on extinguishment of debt of $0 in Q1 2026.
- How has BridgeBio Pharma's gain (loss) on extinguishment of debt changed year-over-year?
- BridgeBio Pharma's gain (loss) on extinguishment of debt increased by 100.0% year-over-year, from -$21.16M to $0.
- What is the long-term trend for BridgeBio Pharma's gain (loss) on extinguishment of debt?
- Over 4 years (2021 to 2025), BridgeBio Pharma's gain (loss) on extinguishment of debt has grown at a 58.7% compound annual growth rate (CAGR), from -$3.34M to -$21.16M.
- What does gain (loss) on extinguishment of debt mean?
- Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.
Ask your AI about BridgeBio Pharma's gain (loss) on extinguishment of debt.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude